Profil
Bradley Hodges has founded Prothelia, Inc. in 2007, where he holds the title of Chief Scientific Officer.
Currently, he is a Partner at CureDuchenne Ventures LLC since 2022.
Aktive Positionen von Bradley Hodges
| Unternehmen | Position | Beginn |
|---|---|---|
Prothelia, Inc.
 Prothelia, Inc. BiotechnologyHealth Technology Prothelia, Inc. operates as a biotechnological company that engages in the provision of protein therapy. It focuses on the treatment of congenital muscular dystrophy type 1A. The company was founded by Bradley Hodges and is headquartered in Milford, MA. | Gründer | 01.10.2007 |
CureDuchenne Ventures LLC
 CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Private Equity Investor | 01.05.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
CureDuchenne Ventures LLC
CureDuchenne Ventures LLC Investment ManagersFinance CureDuchenne Ventures LLC (CureDuchenne Ventures) is a venture capital subsidiary of CureDuchenne, founded in 2014 by Debra Miller. The firm is headquartered in Newport Beach, California. | Finance |
Prothelia, Inc.
Prothelia, Inc. BiotechnologyHealth Technology Prothelia, Inc. operates as a biotechnological company that engages in the provision of protein therapy. It focuses on the treatment of congenital muscular dystrophy type 1A. The company was founded by Bradley Hodges and is headquartered in Milford, MA. | Health Technology |